Neuraxis 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- NeurAxis reported 3rd quarter fiscal year 2026 revenue of $2 million, up 150% from $811,000 in the 3rd quarter of 2025, marking its strongest quarterly revenue performance to date.
- Revenue for the 9 months ended September 30th, 2026 was $5.6 million, up 114% from $2.6 million for the 9 months ended September 30th, 2025.
- iB-Stem unit deliveries increased 92% for the 3 months and 60% for the 9 months ended September 30th, 2026, compared with the prior-year periods.
- For the 3rd quarter of 2026, average selling price was $1,045 per device, up 35% from $775 in the 3rd quarter of 2025; for the 9 months ended September 30th, 2026, it was $1,018, up 32% from $773.
- Gross margin was 86.6% in the 3rd quarter of 2026, compared with 83.3% in the 3rd quarter of 2025, and was 86.3% for the 9 months ended September 30th, 2026, compared with 83.8% in the prior-year period.
- Total operating expenses were $8.3 million in the 3rd quarter of 2026; excluding $4.3 million of one-time stock compensation charges, they were $4 million, up 45% from $2.8 million.
- The 3rd quarter of 2026 operating loss was $6.6 million and net loss was $6.5 million; excluding the one-time $4.3 million stock compensation charge, operating loss was $2.3 million and net loss was $2.2 million.
- Cash on hand as of September 30th, 2026 was $4.5 million, and free cash outflow was $2.3 million for the 3rd quarter and $4.5 million for the 9 months ended September 30th, 2026.
- NeurAxis reported approximately 147 million covered lives after adding 2 large payers in the prior 45 days, and 27 states had CPT-64567 on their Medicaid fee schedules.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and welcome to the NeurAxis third quarter fiscal year 2026 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one on your touchtone phones. To withdraw your questions, you may press star and two. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Ben Shamsian, Investor Relations. Please go ahead. Thank you.
Good morning, everyone, and thank you all for joining us for NeurAxis' third quarter 2026 financial results and corporate update conference call. Joining us on the call is Brian Carrico, CEO of NeurAxis, and Tim Henrichs, the CFO of NeurAxis. At the conclusion of today's prepared remarks, we will open the call to questions. Please follow the operator's instructions to ask questions. Today's event is being recorded and will be available for replay through the webcast information provided in the press release. Finally, I'd like to call your attention to the customary safe harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations, and future potential operating results of NeurAxis. Although management believes these statements are reasonable based on estimates, assumptions, and projections as of today, these statements are not guarantees of future performance.
Time-sensitive information may no longer be accurate at the time of any telephonic or webcast replay. Actual results may differ materially as a result of risks, uncertainties, and other factors, including but not limited to the factors set forth in the company's filings with the SEC. NeurAxis undertakes no obligation to update or revise any of these forward-looking statements. With that said, I would like to now turn the call over to Brian Carrico, Chief Executive Officer of NeurAxis.
Brian, please proceed. Thank you, Ben, and good morning to everyone joining us.
Q3 2026 was an important quarter for NeurAxis, and I look forward to delivering several key updates today. NeurAxis generated third quarter revenue of $2 million, an increase of roughly 150% over the third quarter of 2025. Our results reflect continued progress converting insurance coverage and physician demand into reimbursed IB-Stim treatments. We also continue to expand covered lives and market access. With the addition of two large payers over the past 45 days, our coverage footprint now includes approximately 147 million covered lives. We are now aligning our commercial investment with that broader opportunity by strengthening our commercial footprint, including leadership, marketing, and sales presence in markets with favorable reimbursement. Our priorities are to secure additional payer coverage and increase utilization in markets where coverage is already in place. Those priorities guide our hiring, account selection, and capital allocation.
Q3 was our third full quarter operating with the Cat 1 CPT code for percutaneous electrical nerve field stimulation, or PENFS. Our experience continues to show that utilization is strongest when payer coverage, physician engagement, and the clinical capacity are aligned. We are applying those lessons as we expand the commercial organization. Average selling prices remain strong as the mix continued to shift towards reimbursed treatments and away from discounted financial assistance programs. That shift supports higher revenue per device and gross margin potential. Tim Henrichs, our CFO, will discuss the financial results in more detail. During the call, I will discuss certain areas we view as most important to the success of NeurAxis. I will begin with insurance coverage and our operating metrics, then discuss commercial execution, the VA opportunity, and our priorities for the coming quarters.
Insurance policy coverage remains the single most important driver of scalable growth. Therefore, I was pleased to announce the addition of two large payers, as mentioned earlier, in the last 45 days, bringing our total lives to 147 million. The recent payer additions expand access across several markets and increase the proportion of covered lives within many individual states. We expect these policies to contribute to growth in the fourth quarter, with a more meaningful impact in 2027 as providers implement coverage and our expanded field organization gains traction. Coverage across a meaningful share of a hospital's payer mix gives physicians and administrators greater confidence to establish an IB-Stim program and dedicate clinic capacity. We continued the elevated intensity of our market access strategy, including a national search and hire of who I believe is the strongest med tech-specific market access executive in the country.
Misty has only been here 60 days, and we are already seeing the direct results of her experience and relationships with commercial insurers, Medicaid, and managed Medicaid organizations. We continue to engage directly with payer decision-makers, supported by physician and academic society advocacy, published clinical evidence, treatment guidelines, and existing coverage decisions. We are encouraged by our progress with the additional large and smaller payers, although the timing of new policies continues to remain difficult to predict. We are also working to translate coverage decisions into usable reimbursement. This includes supporting the addition of CPT 64567 to state Medicaid fee schedules and expanding internal prior authorization support to reduce the administrative burden on providers. One example of a short-term hurdle is in states where Medicaid fee schedule implementation remains incomplete. We see account activation and program expansion.
A second example of a short-term hurdle is one of our newest major payers was authorizing one device rather than the full four-device treatment course. That issue remained unsolved more than 30 days into the fourth quarter, was temporarily limiting utilization under the new policy, but we do expect it to be corrected in the coming days. These implementation steps help explain why a coverage announcement and the resulting revenue contribution do not occur at the same time. Our market access and commercial teams are focused on closing that gap while continuing to pursue additional coverage. Furthermore, we continue to make significant progress with many of the remaining large and smaller payers. We are cautiously optimistic that these efforts will result in additional coverage in the coming months. We will continue to provide meaningful KPIs each quarter.
Our operating metrics help investors evaluate whether broader coverage is translating into more treatments and stronger account productivity. Alongside revenue and average selling price, we track ordering accounts, revenue per account, prior authorization approvals, and reimbursement availability. From IB-Stim revenue standpoint, $5.5 million in 2026 versus $2.6 million in 2025, up 112%. IB-Stim average selling price, $1,018 in 2026 versus $773 in 2025, up 32%. Total covered lives, 147 million. Year-to-date internal prior auth approval percentage. I have three numbers for you here. As you remember, 12% was the number through 2025. As of 9/30, we were at 32%. As of 10/30, just over a week ago, we went to 38%. Year-to-date number of ordering accounts, 97 IB-Stim accounts have ordered year-to-date versus 77 at the same point last year, up 26%.
Year-to-date revenue per ordering IB-Stim account, $57 in 2026 versus $33,000 in 2025, up 73%. States with the CPT 64567 on the fee schedule as of today, 27. 27 of the 50 states. Our state coverage profile also helps guide commercial investment. The current breakdown of our commercial insurance policy includes four states with coverage of 70%-76%, four states with 60%-69% coverage, five states with 50%-59% coverage, and seven states with 40%-49% coverage. We are using this geographic concentration to prioritize field resources where access can support greater utilization. Our commercial strategy is to increase treatment volume in markets where favorable coverage and patient demand are already in place. We are prioritizing hospitals based on reimbursement, patient opportunity, and their ability to dedicate clinical capacity to IB-Stim.
The strongest accounts share three characteristics: meaningful payer coverage, an engaged physician champion, and a consistent process for identifying, authorizing, and treating eligible patients. Our field teams work with each institution to address the gaps that limit utilization, whether those involve reimbursement, clinical education, referral development, or clinic workflow. Our recent experience in more concentrated territories supports the value of frequent in-person engagement. A smaller geographic territory allows the salespeople to spend more time with clinicians and hospital teams, resolve reimbursement and operational questions, and support a more consistent treatment process. We are applying that approach as we expand our direct sales presence. We are well into the process of adding at least five additional full-time sales territories in markets with established insurance coverage.
These investments are intended to deepen utilization within existing accounts and support new account development where we see a clear opportunity for patient access and treatment growth. The Chief Commercial Officer and Vice President of Market Access we added in Q3 provide dedicated leadership for this expansion. Our Chief Commercial Officer brings experience building medical technology businesses and sales organizations, including experience at Guidant, Boston Scientific, and NICO. His focus is on field execution, sales team development, and accountability. Our market access leader is focused on securing additional coverage and resolving reimbursement barriers. We have also strengthened clinical education and account development. Our senior medical science liaison supports physician education through grand rounds, divisional presentations, and other clinical programs. Our strategic clinical adoption director works with institution and referral networks to support the integration of IB-Stim into the treatment pathway.
Our new marketing manager is strengthening sales training and helping the field organization communicate the clinical reimbursement and economic value of IB-Stim. in October, we also launched a targeted digital campaign directed at patients and healthcare providers in markets with favorable coverage. It's early, and we expect to begin evaluating the initial response in the coming weeks. We are coordinating these resources within selected regions so that payer support, clinical education, field sales, and targeted marketing reinforce one another to help hospitals treat more eligible patients and make better use of the coverage already in place. Clinic capacity, referral awareness, and hospital economics remain important constraints. Clinical support must be matched by available appointment time, workable authorization processes, and a clear economic case for administrators to commit resources. Our expanded commercial team is focused on those practical requirements. This investment will increase near-term expenses.
We believe the broader reimbursement opportunity supports the expansion, and we remain focused on deploying capital where it can improve utilization and support sustained revenue growth. Tim will address the financial implications in his remarks. The pediatric commercial market remains our primary focus, but I now want to spend a few minutes on the Veterans Administration opportunity. The VA provides an additional growth opportunity through our Federal Supply Schedule contract, which enables commercial access to the U.S. Department of Veterans Affairs. As previously announced, we were awarded a Federal Supply Schedule contract, enabling commercial access to the U.S. Department of Veterans Affairs. We continue to see orders and reorders from multiple VA facilities, with additional facilities moving through activation. That early activity supports our view that the VA can become a meaningful channel over time.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
